ESTRO Brachytherapy for Prostate Cancer 2018

Overall, patients treated with PB have exceptionally good long-term disease outcomes and compare favorably with other treatment modalities.

For LR and fIR: bPFS, CSS and OS are 77-95%, 93-99% and 81- 99%

For IR, bPFS, CSS and OS are 88-95%, 98-77% and 77%

For IR and HR , bPFS, CSS and OS are 68-95%, 95-98% and 57- 79%

for HR, bPFS, CSS and OS are 80-92%, 86-98% and 68-97%